Nothing Special   »   [go: up one dir, main page]

PA8601201A1 - Ligandos del receptor cannabinoide y usos de los mismos - Google Patents

Ligandos del receptor cannabinoide y usos de los mismos

Info

Publication number
PA8601201A1
PA8601201A1 PA20048601201A PA8601201A PA8601201A1 PA 8601201 A1 PA8601201 A1 PA 8601201A1 PA 20048601201 A PA20048601201 A PA 20048601201A PA 8601201 A PA8601201 A PA 8601201A PA 8601201 A1 PA8601201 A1 PA 8601201A1
Authority
PA
Panama
Prior art keywords
cannabinoid
same
receiver
ligands
receiver ligands
Prior art date
Application number
PA20048601201A
Other languages
English (en)
Inventor
Philip Albert Carpino
Robert Lee Dow
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PA8601201A1 publication Critical patent/PA8601201A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE DESCRIBEN EN EL PRESENTE DOCUMENTO COMPUESTOS DE FORMULA (1) Y (11) QUE ACTUAN COMO LIGANDOS DEL RECEPTOR CANNABINOIDE Y SUS USOS EN EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON LA MEDIACION DE RECEPTORES CANNABINOIDES EN ANIMALES.
PA20048601201A 2003-04-23 2004-04-22 Ligandos del receptor cannabinoide y usos de los mismos PA8601201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46483103P 2003-04-23 2003-04-23

Publications (1)

Publication Number Publication Date
PA8601201A1 true PA8601201A1 (es) 2004-12-16

Family

ID=33310962

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20048601201A PA8601201A1 (es) 2003-04-23 2004-04-22 Ligandos del receptor cannabinoide y usos de los mismos

Country Status (29)

Country Link
US (3) US7145012B2 (es)
EP (1) EP1622909A1 (es)
JP (2) JP3911285B2 (es)
KR (1) KR20060006057A (es)
CN (1) CN1777605A (es)
AP (1) AP2005003426A0 (es)
AR (1) AR044038A1 (es)
AU (1) AU2004232553A1 (es)
BR (1) BRPI0409701A (es)
CA (1) CA2523364A1 (es)
CL (1) CL2004000860A1 (es)
CO (1) CO5640111A2 (es)
EA (1) EA200501430A1 (es)
EC (1) ECSP056116A (es)
GT (1) GT200400078A (es)
IS (1) IS8032A (es)
MA (1) MA27767A1 (es)
MX (1) MXPA05011361A (es)
NL (1) NL1026028C2 (es)
NO (1) NO20054407L (es)
OA (1) OA13048A (es)
PA (1) PA8601201A1 (es)
PE (1) PE20050097A1 (es)
TN (1) TNSN05271A1 (es)
TW (1) TW200424207A (es)
UA (1) UA79369C2 (es)
UY (1) UY28277A1 (es)
WO (1) WO2004094429A1 (es)
ZA (1) ZA200507350B (es)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1558252B1 (en) * 2002-08-02 2007-10-10 Merck & Co., Inc. Substituted furo [2,3-b]pyridine derivatives
WO2004041274A1 (en) * 2002-11-05 2004-05-21 Arena Pharmaceuticals, Inc. Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof
WO2004083388A2 (en) * 2003-03-14 2004-09-30 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) * 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
EP1622876A1 (en) * 2003-05-07 2006-02-08 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
US7232823B2 (en) * 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
JP4782003B2 (ja) * 2003-06-17 2011-09-28 アリーナ ファーマシューティカルズ， インコーポレイテッド ５ｈｔ２ｃレセプター関連疾患の処置に有用なベンズアゼピン誘導体
EA200600071A1 (ru) * 2003-06-20 2006-08-25 Арена Фармасьютикалз, Инк. Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором
US20050026983A1 (en) * 2003-07-30 2005-02-03 Pfizer Inc Imidazole compounds and uses thereof
NZ545836A (en) * 2003-09-17 2009-09-25 Janssen Pharmaceutica Nv Fused heterocyclic compounds as serotonin receptor modulators
EP1675833B1 (en) * 2003-10-20 2011-01-26 Abbott Healthcare Products B.V. 1h-imidazole derivatives as cannabinoid receptor modulators
US7271189B2 (en) * 2003-10-20 2007-09-18 Solvay Pharmaceuticals, Inc. 1H-imidazole derivatives as cannabinoid receptor modulators
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
CA2544191A1 (en) * 2003-11-04 2005-05-26 Merck & Co., Inc. Substituted naphthyridinone derivatives
US7151097B2 (en) * 2003-11-07 2006-12-19 Pfizer Inc. Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
CA2561305C (en) * 2004-03-24 2013-07-30 Bharat Lagu Tetrahydro-indazole cannabinoid modulators
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
EP2286838A3 (en) * 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and related disorders
EA201100129A1 (ru) * 2004-12-23 2011-10-31 Арена Фармасьютикалз, Инк. Композиции и способы применения модулятора рецептора 5ht-2c
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
MX2007012233A (es) * 2005-03-31 2008-03-18 Johnson & Johnson Moduladores canabinoides de tetrahidrotiopirano pirazol.
WO2006129193A2 (en) * 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
AU2006255097B2 (en) * 2005-06-06 2012-02-09 Georgetown University Compositions and methods for lipo modeling
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
WO2007055743A2 (en) * 2005-11-01 2007-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
AU2007222069A1 (en) * 2006-02-21 2007-09-13 Ampla Pharmaceuticals Inc. CB1 antagonists and inverse agonists
MEP6808A (xx) 2006-02-23 2010-02-10 Lundbeck & Co As H Priperidinoilpirodolini agonisti receptora menalokortina tipa 4
AU2007226673A1 (en) * 2006-03-10 2007-09-20 Jenrin Discovery Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
KR100997601B1 (ko) 2006-03-30 2010-11-30 아이알엠 엘엘씨 카나비노이드 1 활성의 억제제로서의 아졸로피리미딘
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
EP2057144A4 (en) * 2006-09-01 2010-06-02 Hetero Drugs Ltd NEW POLYMORPHIC FROM RIMONABANT
MX2009004314A (es) 2006-11-13 2009-05-05 Pfizer Prod Inc Diaril, dipiridinil y arilpiridinilderivados y usos de los mismos.
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2008083442A1 (en) * 2007-01-10 2008-07-17 Brc Operations Pty Limited Method for formulating combination medications for adhd
WO2008115880A2 (en) * 2007-03-21 2008-09-25 The Board Of Regents Of The University Of Texas System Use of leptin for the treatment or prevention of parkinson's disease
PE20090142A1 (es) * 2007-04-11 2009-02-19 Merck & Co Inc Derivados de furo[2,3-b] piridina sustituidos como moduladores del receptor canabinoide-1
MY146924A (en) * 2007-06-21 2012-10-15 Cara Therapeutics Inc Substituted imidazoheterocycles
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8133904B2 (en) * 2007-09-07 2012-03-13 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
EP2196459B1 (en) 2007-09-28 2016-11-02 Takeda Pharmaceutical Company Limited 5-membered heterocyclic compound
EA201070609A1 (ru) * 2007-11-14 2010-12-30 Амилин Фармасьютикалз, Инк. Способы лечения ожирения и ассоциированных с ожирением заболеваний и расстройств
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
CN102015591B (zh) * 2008-03-04 2014-01-29 艾尼纳制药公司 制备与5-ht2c激动剂(r)-8-氯-1-甲基-2，3，4，5-四氢-1h-3-苯并氮杂卓相关的中间体的方法
EP2116618A1 (en) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnosis and treatment of Kawasaki disease
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
KR101280786B1 (ko) 2008-08-06 2013-07-05 화이자 리미티드 멜라노코르틴 4 작용제로서 다이아제핀 및 다이아조칸 화합물
JP2012505231A (ja) * 2008-10-08 2012-03-01 ブリストル−マイヤーズ スクイブ カンパニー アゾロピロロンメラニン凝集ホルモン受容体−１アンタゴニスト
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EP2480082A4 (en) 2009-09-25 2014-01-15 Merck Sharp & Dohme SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OF DIABETES
WO2011153206A1 (en) 2010-06-02 2011-12-08 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-ht2c receptor agonists
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
CN103189360A (zh) 2010-09-01 2013-07-03 艾尼纳制药公司 5-ht2c激动剂的非吸湿性盐
AU2011296003B2 (en) 2010-09-01 2015-11-12 Arena Pharmaceuticals, Inc. Modified-release dosage forms of 5-HT2C agonist useful for weight management
AU2011296014A1 (en) 2010-09-01 2013-04-04 Arena Pharmaceuticals, Inc. Salts of lorcaserin with optically active acids
NZ630494A (en) 2010-09-01 2016-05-27 Arena Pharm Inc Administration of lorcaserin to individuals with renal impairment
CA2726085A1 (en) * 2010-12-20 2012-06-20 Bernard Le Foll User of marihuana and compounds therein for treating obesity
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US20120282255A1 (en) * 2011-04-07 2012-11-08 Greg Plucinski Methods and compositions for the treatment of alcoholism and alcohol dependence
JO3357B1 (ar) * 2012-01-26 2019-03-13 Novartis Ag مركبات إيميدازوبيروليدينون
JP6171003B2 (ja) 2012-05-24 2017-07-26 ノバルティス アーゲー ピロロピロリジノン化合物
PE20151139A1 (es) * 2012-08-16 2015-08-07 Janssen Pharmaceutica Nv Pirrolopirazoles como bloqueadores del canal de calcio tipo n
CA2882038A1 (en) 2012-08-16 2014-02-20 Janssen Pharmaceutica Nv Substituted pyrazoles as n-type calcium channel blockers
CA2886875A1 (en) 2012-10-09 2014-04-17 Arena Pharmaceuticals, Inc. Method of weight management
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
WO2014191894A1 (en) 2013-05-27 2014-12-04 Novartis Ag Imidazopyrrolidinone derivatives and their use in the treatment of disease
MX2015016425A (es) 2013-05-28 2016-03-03 Novartis Ag Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
CA2912986A1 (en) 2013-05-28 2014-12-04 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
EA029269B1 (ru) 2013-11-21 2018-02-28 Новартис Аг Производные пирролопирролона и их применение для лечения заболеваний
US10683294B2 (en) * 2017-05-31 2020-06-16 Chemocentryx, Inc. 5-5 fused rings as C5a inhibitors
CN110997674B (zh) 2017-05-31 2022-12-20 凯莫森特里克斯股份有限公司 作为C5a抑制剂的6-5稠合环类
CN111788184B (zh) * 2017-12-22 2023-12-22 凯莫森特里克斯股份有限公司 用作C5aR抑制剂的二芳基取代的5,5-稠合环化合物
EP3728203B1 (en) * 2017-12-22 2024-03-13 ChemoCentryx, Inc. DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS
AR114464A1 (es) * 2018-04-02 2020-09-09 Chemocentryx Inc PROFÁRMACOS DE ANTAGONISTAS DE C5aR BICÍCLICOS FUSIONADOS
US10897925B2 (en) 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers
US20200035118A1 (en) 2018-07-27 2020-01-30 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes
US11504416B2 (en) 2018-09-04 2022-11-22 Paw Power, Inc. Formulation with cannabinoids
US11839663B2 (en) * 2019-09-30 2023-12-12 Janssen Pharmaceutica Nv Radiolabelled MGL pet ligands
WO2022258052A1 (zh) * 2021-06-11 2022-12-15 劲方医药科技(上海)有限公司 杂环内酰胺类化合物，其制法与医药上的用途

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US224970A (en) * 1880-02-24 Hand-tool for dressing millstones
US3365459A (en) * 1964-09-08 1968-01-23 Ciba Geigy Corp Certain tetrahydro pyrazolo-pyridine and pyrazolo-piperidine derivatives
US3340269A (en) * 1964-09-08 1967-09-05 Ciba Geigy Corp 1-substituted 4-acyl-2, 3-dioxo-piperidine
US3423414A (en) 1966-01-13 1969-01-21 Ciba Geigy Corp Pyrazolopyridines
US3526633A (en) * 1968-03-06 1970-09-01 American Cyanamid Co Substituted 2,4,5,6-tetrahydropyrrolo(3,4-c)pyrazoles
DE3204713A1 (de) * 1982-02-11 1983-08-18 Basf Ag, 6700 Ludwigshafen Aminopyrazolverbindungen
SU1069387A1 (ru) * 1982-07-01 1985-11-30 Институт физико-органической химии и углехимии АН УССР Дигидрохлорид 5-/ @ -( @ -анизил)- @ -оксиэтил/ 2-(3,4-диметоксифенил)-1-метил-4,5,6,7-тетрагидроимидазо(4,5- @ )пиридина,обладающий спазмолитическим действием
GB8613591D0 (en) 1986-06-04 1986-07-09 Roussel Lab Ltd Chemical compounds
US5078780A (en) * 1986-10-22 1992-01-07 Ciba-Geigy Corporation 1,5-diphenylpyrazole-3-carboxylic acid derivatives for the protection of cultivated plants
AU611437B2 (en) 1987-05-29 1991-06-13 Ortho Pharmaceutical Corporation Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-n-hydroxypropanamides and method for synthesizing the same
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
FR2665898B1 (fr) 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
CH681806A5 (es) 1991-03-19 1993-05-28 Ciba Geigy Ag
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
CA2166721C (en) 1993-07-06 1999-07-27 Allen Jacob Duplantier Bicyclic tetrahydro pyrazolopyridines
FR2714057B1 (fr) * 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
US5508300A (en) * 1994-01-14 1996-04-16 Pfizer Inc. Dihydro pyrazolopyrroles, compositions and use
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2741621B1 (fr) 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2742148B1 (fr) 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
DE69822449T2 (de) 1997-01-21 2005-01-27 Smithkline Beecham Corp. Neue cannabinoidrezeptor-modulatoren
FR2758723B1 (fr) 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2761266B1 (fr) * 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
WO1999046267A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
FR2783246B1 (fr) 1998-09-11 2000-11-17 Aventis Pharma Sa Derives d'azetidine, leur preparation et les medicaments les contenant
IL141769A0 (en) 1998-09-11 2002-03-10 Aventis Pharma Sa Azetidine derivatives, preparation and medicines containing them
FR2789079B3 (fr) 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
EP1173438A1 (en) 1999-04-16 2002-01-23 Novo Nordisk A/S Substituted imidazoles, their preparation and use
FR2799124B1 (fr) 1999-10-01 2004-08-13 Sanofi Synthelabo Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
AU780572B2 (en) 1999-10-18 2005-04-07 University Of Connecticut, The Pyrazole derivatives as cannabinoid receptor antagonists
DE60030303T2 (de) 1999-10-18 2007-10-11 The University Of Connecticut, Farmington Cannabimimetische indolderivate
FR2800372B1 (fr) 1999-11-03 2001-12-07 Sanofi Synthelabo Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant
FR2800375B1 (fr) 1999-11-03 2004-07-23 Sanofi Synthelabo Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
HUP0202263A3 (en) 1999-12-27 2003-02-28 Japan Tobacco Inc Benzimidazole, indole and imidazo-pyridine derivatives and pharmaceutical compositions containing them
FR2804604B1 (fr) 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
AU2001234958A1 (en) 2000-02-11 2001-08-20 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
US6355631B1 (en) 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
US6566356B2 (en) * 2000-03-03 2003-05-20 Aventis Pharma S.A. Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
US6479479B2 (en) * 2000-03-03 2002-11-12 Aventis Pharma S.A. Azetidine derivatives, their preparation and pharmaceutical compositions containing them
ES2272449T3 (es) * 2000-03-23 2007-05-01 Solvay Pharmaceuticals B.V. Derivados de 4,5-dihidro-1h-pirazol con actividad antagosnista de cb-1.
FR2809621B1 (fr) 2000-05-12 2002-09-06 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles comme antidiarrheiques
US20020019421A1 (en) * 2000-07-05 2002-02-14 Roni Biberman Compositions and therapy for substance addiction
US20020091114A1 (en) * 2000-10-04 2002-07-11 Odile Piot-Grosjean Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
ES2294047T3 (es) 2000-12-28 2008-04-01 Ono Pharmaceutical Co., Ltd. Un compuesto de ciclopenta (d) pirazolo(1,5-a) pirimidina como antagonista del receptor de crf.
RU2281941C2 (ru) 2001-03-22 2006-08-20 Солвей Фармасьютикалс Б.В. Производные 4,5-дигидро-1h-пиразола, обладающие cb1-антагонистической активностью
ITMI20011483A1 (it) 2001-07-11 2003-01-11 Res & Innovation Soc Coop A R Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi
EP1411928A1 (en) 2001-07-20 2004-04-28 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
AU2002319627A1 (en) * 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
FR2829028B1 (fr) 2001-08-29 2004-12-17 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
FR2829027A1 (fr) 2001-08-29 2003-03-07 Aventis Pharma Sa Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson
CA2457922A1 (en) 2001-08-31 2003-03-13 University Of Connecticut Novel pyrazole analogs acting on cannabinoid receptors
TWI231757B (en) 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
CN101195604A (zh) 2001-09-21 2008-06-11 索尔瓦药物有限公司 具有效cb1-拮抗活性的4,5-二氢-1h-吡唑衍生物
DE60215960T2 (de) 2001-09-21 2007-03-01 Solvay Pharmaceuticals B.V. Neue 4,5-dihydro-1h-pyrazol-derivate mit cb1-antagonistischer wirkung
US6509367B1 (en) 2001-09-22 2003-01-21 Virginia Commonwealth University Pyrazole cannabinoid agonist and antagonists
US7071207B2 (en) 2001-09-24 2006-07-04 Bayer Pharmaceuticals Corporation Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity
AR036608A1 (es) 2001-09-24 2004-09-22 Bayer Corp Derivados de imidazol, composiciones farmaceuticas y el uso de dichos derivados para la fabricacion de un medicamento para el tratamiento de la obesidad
EP1432679A1 (en) 2001-09-24 2004-06-30 Bayer Pharmaceuticals Corporation Preparation and use of pyrrole derivatives for treating obesity
SE0104330D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
SE0104332D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
US20030139386A1 (en) * 2001-12-21 2003-07-24 Sophie Cote Pharmaceutical compositions based on azetidine derivatives
WO2003075660A1 (en) 2002-03-06 2003-09-18 Merck & Co., Inc. Method of treatment or prevention of obesity
DE60334787D1 (de) 2002-03-12 2010-12-16 Merck Sharp & Dohme Substituierte amide
AR038966A1 (es) 2002-03-18 2005-02-02 Solvay Pharm Bv Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
CA2479618A1 (en) 2002-03-26 2003-10-09 William K. Hagmann Spirocyclic amides as cannabinoid receptor modulators
ES2192494B1 (es) 2002-03-27 2005-02-16 Consejo Superior De Investigaciones Cientificas Derivados de 1,2,4-triazol con propiedades cannabinoides.
CA2479744A1 (en) 2002-03-28 2003-10-09 Paul E. Finke Substituted 2,3-diphenyl pyridines
FR2837706A1 (fr) 2002-03-28 2003-10-03 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides cb1 pour la preparation de medicaments utiles pour traiter les dysfonctionnements sexuels et/ou ameliorer les performances sexuelles
US20050154202A1 (en) 2002-04-05 2005-07-14 Hagmann William K. Substituted aryl amides
FR2838439B1 (fr) 2002-04-11 2005-05-20 Sanofi Synthelabo Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant
EP1499306A4 (en) 2002-04-12 2007-03-28 Merck & Co Inc BICYCLIC AMIDE
US6825209B2 (en) * 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
ES2287476T3 (es) 2002-05-10 2007-12-16 Smithkline Beecham Corporation Pirazolopirimidinas sustituidas.
DE60325243D1 (de) 2002-08-02 2009-01-22 Warsaw Orthopedic Inc Systeme und techniken zur beleuchtung eines operationsraums
US20040077650A1 (en) * 2002-10-18 2004-04-22 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof

Also Published As

Publication number Publication date
US20060205948A1 (en) 2006-09-14
US20060205720A1 (en) 2006-09-14
ECSP056116A (es) 2006-03-01
CL2004000860A1 (es) 2005-03-18
ZA200507350B (en) 2006-11-29
US7241788B2 (en) 2007-07-10
NL1026028C2 (nl) 2005-07-05
MXPA05011361A (es) 2005-11-28
TNSN05271A1 (fr) 2007-07-10
WO2004094429A1 (en) 2004-11-04
EA200501430A1 (ru) 2006-06-30
US7145012B2 (en) 2006-12-05
TW200424207A (en) 2004-11-16
CN1777605A (zh) 2006-05-24
US20040214855A1 (en) 2004-10-28
PE20050097A1 (es) 2005-03-21
CA2523364A1 (en) 2004-11-04
OA13048A (en) 2006-11-10
IS8032A (is) 2005-09-15
UY28277A1 (es) 2004-11-30
GT200400078A (es) 2005-03-03
UA79369C2 (en) 2007-06-11
CO5640111A2 (es) 2006-05-31
AU2004232553A1 (en) 2004-11-04
JP2007084553A (ja) 2007-04-05
MA27767A1 (fr) 2006-02-01
US7230024B2 (en) 2007-06-12
JP2006524228A (ja) 2006-10-26
NO20054407L (no) 2005-12-15
NO20054407D0 (no) 2005-09-22
BRPI0409701A (pt) 2006-05-02
AR044038A1 (es) 2005-08-24
NL1026028A1 (nl) 2004-10-27
AP2005003426A0 (en) 2005-12-31
KR20060006057A (ko) 2006-01-18
JP3911285B2 (ja) 2007-05-09
EP1622909A1 (en) 2006-02-08

Similar Documents

Publication Publication Date Title
PA8601201A1 (es) Ligandos del receptor cannabinoide y usos de los mismos
UY28278A1 (es) Ligandos del receptor cannabinoide y usos de los mismos
ECSP056117A (es) Ligandos de receptores de cannabinoides y sus usos
ECSP055945A (es) Compuestos de pirazolotriazina y usos de los mismos
UY28275A1 (es) Ligandos de receptores de cannabinoides y sus usos
CR7812A (es) Compuestos de purina y usos de los mismos como ligandos de receptor de cannabinoides
ECSP066549A (es) Compuestos de pirazolilo e imidazolilo bicíclicos y usos de los mismos
CR7168A (es) Ligandos del receptor de 5.ht y sus usos
UY29478A1 (es) Compuestos heteroaromaticos acilaminobiciclicos y sus usos
MXPA05007938A (es) Ligandos de receptores de cannabinoides y usos de los mismos.
MXPA05013294A (es) Ligandos del receptor de cannabinoides y usos de los mismos.
MXPA05013282A (es) Derivados de pirimidina como ligandos del receptor de cannabinoides.
MXPA05011922A (es) Ligandos del receptor de cannabinoides y sus usos.
CR8052A (es) Ligandos del receptor cannabinoide y usos de los mismos
DOP2004000883A (es) Ligandos del receptor cannabinoide y usos de los mismos
DOP2004000885A (es) Ligandos de receptor cannabinoide y usos de los mismo
DOP2004000884A (es) Ligandos de receptores de cannabinoides y sus usos
DOP2004000810A (es) Compuestos de pirazolotriazina y usos de los mismos
UY28599A1 (es) Compuestos de pirazolilo e imidazolilo bicíclicos y usos de los mismos
CR7169A (es) Ligandos del receptor de 5-ht y sus usos